Up to now, multiple types of cancers demonstrated favorable outcome after immunotherapy of PD-1/PD-L1 blockade including lung cancer, melanoma, breast cancer, and renal cancer [7, 8]. This evidence concerns the gene PDCD1 and breast cancer.